Physician profile
Michael J Williamson
NPI 1366581209
$1,036.31
in general payments reported to CMS, 2019-2025
20 companies · $225 in 2025
The $225 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $82.44 · 2021: $46.78 · 2022: $188 · 2023: $154 · 2024: $340 · 2025: $225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $644 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $644.06 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $178.48 | 2022-2025 | |
| Janssen Biotech, INC. | $160.66 | 2020-2025 | Talvey, Darzalex, Tecvayli |
| Astellas Pharma US INC | $88.96 | 2024 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $65.19 | 2022-2024 | Opdivo |
| Pharmacyclics LLC, An Abbvie Company | $60.99 | 2020 | |
| Genzyme Corporation | $55.97 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $48.97 | 2023-2025 | |
| Gilead Sciences, INC. | $44.59 | 2021-2023 | Trodelvy |
| Inari Medical, INC. | $42.26 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Coherus Oncology, INC. | $40.65 | 2022 | |
| Abbvie INC. | $40.44 | 2024-2025 | |
| Lilly USA, LLC | $39.63 | 2023-2024 | Jaypirca, Retevmo, Verzenio |
| Merck Sharp & Dohme LLC | $39.05 | 2021-2025 | Welireg, Keytruda |
| Sun Pharmaceutical Industries INC. | $32.67 | 2023-2024 | Odomzo, Yonsa |
| Exelixis INC. | $29.46 | 2024 | Cabometyx |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $29.09 | 2023-2025 | Zejula |
| Amgen INC. | $13.84 | 2023 | Blincyto, Kyprolis |
| Daiichi Sankyo INC. | $13.55 | 2022 | |
| Seagen INC. | $11.86 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Williamson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.